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We have extended our studies on the relationship between cisplatin/carboplatin-induced DNA damage in
readilyaccessibletissue(s) andclinicalresponsetotherapy.Suchanapproach mayassistinthestudyofcancer
drug resistance and in establishing parameters for assessing human populations for sensitivity to DNA
damaging agents in the environment. Platinum-DNA adduct levels were measured by atomic absorbance
spectrometry. DNA repair capacity was assessed in human T-lymphocytes by the ability to repair cisplatin
lesions in cellular DNA or in transfected plasmid DNA. In a "blinded" study of 21 patients receiving
combination cisplatin/carboplatin drug therapy, there was a direct relationship between DNA damage in
leukocytes and disease response (summary two-sided p = 0.00011). The cohort of patients had 15 different
tumor types, suggesting that blood tissue and tumor tissue of an individual may process platinum-DNA
damage similarly regardless of the tissue of origin of the tumor. In leukocytes in vivo, persistence and
accumulation were prominent features ofthe cisplatin-DNA adduct profile. Functional DNA repair capacity
hasbeenstudied ineighthumanleukocytecell linesin vitro(three,T-cells; three,B-cells; one, monocytic; one,
promyelocytic), using a host cell reactivation assay with-cisplatin-damaged pRSVcat. In the three T cell lines
studied, host cell reactivation efficiency was directly related to the cells' abilities to repair cisplatin-damaged
cellular DNA (correlation coefficient = 0.993). These data suggest that blood tissue and tumor tissue may
process platinum-DNA adducts similarly on a molecular level and that human T lymphocytes are a suitable
target for a prospective study ofthe impact ofDNA repair on clinical response to platinum compounds.
Introduction
Cisplatin and carboplatin are anticancer therapeutic
agents that are carcinogenic and mutagenic (1,2). These
drugs may induce a number of different cellular effects
through many different mechanisms (1,3); however, direct
covalent binding to DNA with subsequent disruption of
normal DNA function is considered to be the primary
mechanism through which this class of agents effects its
carcinogenic andmutagenicbehavior(1-3).Whereas many
DNA damaging agents may induce deleterious health
effects in humanpopulations (4), fewagents are as amena-
ble to study as platinum compounds: because controlled,
precise doses can be given; there are negligible "back-
ground" levels of these agents in the environment; indi-
viduals exposed to the drugs are monitored for defined
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clinical end points; and the methods for assessing
platinum-DNA damage levels are well established.
Work has been performed by three groups to assess
human patient populations for platinum-DNA damage.
The most extensive set of studies to date has been per-
formed by Reed and Poirier in patients with ovarian or
testicular cancer (5-8). In these studies, which involve
more than 100 patients, the relationship ofplatinum-DNA
damagelevelinperipheralbloodleukocytesisconsistently
and directly related to response for the two diseases.
Further, tumor and bone marrow tissue obtained at
autopsyfrompatientswhohadbeentreatedwithplatinum
compounds have similar levels ofplatinum-DNA adducts
(6,9,10). These studies have received some criticism
because ofthe use ofpolyclonal antisera to detect adducts
in an enzyme-linked immunosorbent assay (ELISA), the
results ofwhich do not correlate well with platinum-DNA
damage levels measued by atomic absorbance spectrome-
try (AAS) (11).
Den Engelse and colleagues have used immunoden-
sitometry to study adduct levels in buccal mucosa cells
from patients receiving cisplatin and carboplatin therapy
(12). Theyfound a directrelationship between adductlevelDABHOLKAR ET AL.
and disease response in their patient cohort, although the
relationship was not statistically significant. This method
has also been criticized because ofthe lack ofa one-to-one
relationship between what is measured in this assay and
what is measured by AAS.
Fichtinger-Schepman and colleagues have used anti-
sera directed against isolated platinum-DNA base ad-
ducts and have also reported a trend to higher adduct
levels in patients who respond to therapy (13). They con-
siderthattheir assayis advantageous because ofthe close
(but not one-to-one) relationship between the measures of
their assay and ofAAS; however, this conclusion is based
onthestudyofaverysmallnumberofsamples(14). Recent
reports byReed and colleagues suggestthat currentAAS
technology may now be used routinely for studies of
platinum-DNA binding following exposure to therapeutic
levels ofthe drugs (9,15,16).
Because of the importance of the questions raised by
studies of this kind, we have conducted two types of
studies in fresh human tissues. In the first, we used AAS
to study platinum-DNA damage in peripheral blood leu-
kocytes from a cohort ofpatients with 15 different tumor
types who had received cisplatin and carboplatin in a
phase-I clinical study(12).Weconsideredthatifplatinum-
DNA adduct levels were directly related to clinical re-
sponse in this mixed cohort ofpatients, itwould suggest a
parallel between blood tissue and tumor tissue in the
processing of platinum-DNA damage, regardless of
tumor type.
In the second set ofstudies, we assessed theusefulness
of a functional cisplatin-DNA adduct repair assay in
human leukocyte cell lines. This host-cell reactivation
assay assesses a cell's ability to express the chloram-
phenicol acetyltransferase gene as a function of the
amountofcisplatin damageintroducedinto aplasmidthat
is transfected into those cells. The assay accurately
reflects the relative cisplatin-DNA adduct repair capa-
bility of human ovarian cancer cells (16,17). The possible
relationships between DNA damage and repair in malig-
nant and nonmalignant cells are discussed.
Methods
Patients Studied and Sample Collection
Twenty-one adultpatients with histological documenta-
tion of cancer were treated in an approved experimental
clinical study of cisplatin and carboplatin given in com-
bination. The study was conducted at the Norris Cancer
Center of the University of Southern California (USC)
School of Medicine, Los Angeles, California. Carboplatin
was given as a 30-min infusion on day 1 and cisplatin as a
30-min infusion on day 3 of28-day treatment cycles (both
drugs were obtained from commercial sources). There
were 15 different histological types ofmalignancy in this
cohort, aslistedinTable1. Details ofpatienteligibilityand
clinical results ofthe study have beenreported elsewhere
(12). Peripheral blood samples were obtained at USC by
venipuncture, andbuffy coats wereprepared as described
previously (5-8).
Table 1. Histological types oftumors seen in a cohort of21 patients
treated with carboplatin and cisplatin therapy.
Timor types ofresponders Timor types ofnonresponders
Breast adenocarcinoma Colon adenocarcinoma
Buccal mucosa, squamous-cell Liver adenocarcinoma
carcinoma
Esophagus, squamous-cell Lung adenocarcinoma
carcinoma
Ovary, adenocarcinoma Lung large-cell carcinoma
Pleural mesothelioma Lung small-cell carcinoma
(two responders) Melanoma
Pancreas, adenocarcinoma
Parotid, adenoid cystic
Parotid, undifferentiated
Uterus, leiomyosarcoma
Blood samples were obtained from all patients at the
same times relative to therapy: a) the morning ofthe first
dose oftherapy, but prior to any therapy (ClDl); b) 24 hr
after the first dose of therapy (C1D2); c) 24 hr after the
second dose oftherapy(C1D4); d) the morning ofthefirst
dose ofthe second cycle oftherapy, but prior to that dose
(C2D1); e) 24 hr after the first dose of the second cycle
(C2D2),i.e.,thethirddoseoftherapy;and]) 24hrafterthe
seconddoseofthesecondcycle(C2D4),i.e.,thefourthdose
oftherapy.
The study was designed to study platinum-DNA ad-
ducts in peripheral blood cells in a "blinded" fashion.
Therefore, all blood samples were obtained as described,
coded, and shipped on dry ice to the Medicine Branch of
theNationalCancerInstitute(NCI),Bethesda,Maryland.
After arrival, theywere stored at -20°C until isolation of
DNA. DNA was isolated (see below) and adduct levels
measuredintheabsenceofanyinformationaboutpatients.
Isolation ofDNA for Measurement of
Platinum-DNA Adducts
DNAwasisolatedinthesamewayfrombuffycoatsfrom
patients and from cell pellets in vitro. Cesium chloride
bouyant density gradient centrifugation was performed
oneachsampleaspreviouslydescribed,yieldingDNAthat
was > 99% free ofcontamination (18).
Cell Lines Studied and Culture Conditions
Eighthumanleukocytecelllineswereobtainedfromthe
American lype Culture Collection(ATCC; Rockville, MD)
andmaintainedincultureaccordingtospecificrecommen-
dations oftheATCC. Theycomprised three Tlymphocyte
cell lines (HuT 78, H9, and MOLT-4), three B lymphocyte
cell lines (WIL2-NS, SKW 6.4, and RPMI 1788), the
monocyte cell line THP-1, and the promyelocytic cell line
HL-60. All cell lines were assayed for sensitivity to
cisplatin by measuring inhibition of growth following
3-day exposures to cisplatin at 0.5-100 ,uM. Cells were
seeded at an initial cell density of5 x 104 cells/mL.
pRSVcat Transfection Assay
The plasmid pRSVcat was propagated and amplified in
Escherichia coli and purified using cesium chloride/
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ethidium bromide density gradient centrifugation ofbac-
terial lysates, as previously described (16,19). Aliquots of
plasmid were modified with cisplatin in the presence of
sodium perchlorate, pH 5.5, as previously described
(16,19). pRSVcatwas transfected into cells byelectropora-
tion under conditions found optimal for undamaged plas-
mid (215 V, 800 ,uF) (19), using 5 x 106 cells in 0.5 mL of
medium. Chloramphenicol acetyltransferase activity was
measured24hrlaterand,insomeexperiments, 48hrlater.
Data Analyses
Patients were grouped according to clinical response to
therapy. Those who had a > 50% decrease in tumormass
were designated as responders, and those who experi-
enceda < 50%decreaseintumormassweredesignatedas
nonresponders. Comparison of adduct levels between
responders and nonresponders on each daywas based on
the Wilcoxon rank sum test (20). A summary comparison
of adduct levels between responders and nonresponders
across all 4 days was performed using the stratified
Wilcoxon rank sum test (20).
For studies in vitro, linear regression analyses were
performedusingthe CricketGraph softwarepackage and
a Macintosh II computer (Apple, Inc.).
Results
Adduct Levels in Peripheral Blood
Leukocytes and Disease Response
Previous studies showed a direct relationship between
DNA adduct levels measured in ELISA and disease
response in ovarian cancer (6,8) and in testicular cancer
(5). Oneshortcomingofthose studiesisthatbloodsamples
for determination of adducts were drawn at the conven-
ience ofthe patient and the physician, and not necessarily
in a systematic fashion, as was done in our study. We
attempted to collect all designated samples from all
patients. Some patients could not cooperate in sample
collection; in other cases, the collected sample contained
such a small number of nucleated blood cells that the
quantity of DNA obtained was insufficient to assay the
adduct level.
Figure 1 shows the results obtained for patients in this
study at C1D2, C1D4, C2D2 and C2D4. Patients who
responded to therapy had consistently higher levels of
platinum-DNA damage than patients who did not
respond. Table 2 shows the same data in tabular form, as
well as theresults ofstatisticalanalyses ofthe differences
between responders and nonresponders. For C1D2 and
C2D4, the differences were statistically significant. For
C1D4 and C2D2, the differences showed a strong trend
toward significance. We nextassessed the collective trend
in the pattern across all 4 days studied and found thatthe
pattern of responders with higher adduct levels than
nonresponders on each of the days studied gives a sum-
mary two-sided p = 0.00011 in this cohort of 21 patients
with 15 different tumor types.
Adduct Accumulation and Persistence in
Peripheral Blood Leukocytes
Although our efforts were focused on collecting all
designatedblood samplesfromcycle 1 oftherapy,wewere
abletocollectadequatebloodsamplesforadductmeasure-
ment on days 1, 2, and 4 of cycles 1 and 2 for only four
individuals (i.e., adequate samples collected on 6 days
studied). The mean values from these determinations are
shown in Figure 2.
Themorningbeforethefirstdoseofcarboplatin (ClDl),
thesefourpatients showednodetectablelevelofplatinum-
DNA adducts in leukocyte DNA. On C1D2 (24 hr after
carboplatin), measurable levels of adduct could be as-
sessed. On C1D4 (24 hr after cisplatin), the average DNA
adductlevelwas greaterthan 40fmole/,ug DNA. On C2D1
(the morning before the second carboplatin dose and 25
daysafterthemostrecentdoseofplatinum), anaverageof
12moleadductremainedoncellularDNAinthesepatients,
suggesting that 30% of the adduct load seen on C1D4
persisted for 25 days after the most recent exposure to
platinum.
On C2D2 (24 hr after the second carboplatin dose), the
incremental rise in adduct levels was about the same as
that seen during the same period in cycle 1. On C2D4,
however, therewas adisproportionate riseinadductlevels
as a result of the D3 cisplatin dose. The incremental
increase inmeasured adductlevel from day2 to day4was
4-fold greater in cycle 2 than in cycle 1. It is unclear
whether this result is due simply to an increase in the
amountofinitial DNAdamage, to apartial inactivation of
DNA repair enzymes from a direct covalent attack of
cisplatin on proteins, or to some combination thereof.
Thesedatashowthatintissuesoflivinghumanpatients
platinum-DNAadductspersistforperiodsof2 25daysand
thatadductaccumulationmayresultfromthispersistence
and/or as a result of other processes. This persistence
reflects the amount ofplatinum-DNA damage that is not
readily repaired by these cells.
DNA Repair ofCistplatin-damaged Plasmid
in Eight Human Leukocyte Cell Lines
Since DNA repair can vary markedly between indi-
viduals and from tissue to tissue within an individual, we
became concerned with developing a way to study DNA
repair for the purpose of comparing one individual to
another. Since peripheral blood appears to be a suitable
surrogate marker for studying platinum-DNA binding
effects, we havebegun to address the question ofwhether
peripheral blood can serve as the basis forinterindividual
comparisons ofDNA repair efficiently.
Asreportedpreviously,we developed arapid single-vial
transfection assay to study cellular repair of cisplatin-
modifiedpRSVcatplasmidinthehuman H9Tlymphocyte
cell line (19). Using the parameters of this assay, we
transfected plasmid into each of eight human leukocyte
cell lines. As shown in Figure 3, the assay was equally
effectiveintransferringplasmid intoeach oftheeightcell
lines studied. In each case, the amount of intracellular
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FIGURE 1. Platinum-DNA adduct levels (measured by atomic absorption spectrometry) areplotted forresponders (RES) and nonresponders (NR) for
each ofthe 4 days following chemotherapy on the first two cycles oftherapy. C1D2 samples were taken 24 hr after the cycle 1 carboplatin dose; C1D4
samples weretaken24 hrafterthecycle 1 cisplatin dose; C2D2, 24 hrafterthecycle 2carboplatin dose; and C2D4, 24 hrafterthecycle 2 cisplatin dose.
Horizontal bars represent median values in each group ofdata points.
Table 2. Platinum-DNA adduct levels and disease response in 21
patients treated with cisplatin and carboplatin (not all patients
had samples that could be evaluated on all days).
Median adduct levelsa
Cycle/day Responders Nonresponders p-Valueb
C1D2 49.2 (6) 14.4 (11) 0.0071
C1D4 105.0 (5) 40.0 (8) 0.097
C2D2 51.6 (4) 26.0 (8) 0.198
C2D4 367.7 (3) 26.3 (5) 0.036
Summary two-sided p = 0.00011
aNumber ofpatients studied in parentheses.
bTwo-sided p-value for comparison of adduct levels of responders
versus nonresponders, Wilcoxon rank sum test.
plasmid remaining after DNAse treatment of cells at the
end of the transfection procedure was about 3% of the
amountofplasmid added to thetransfectionmixture. This
is about the same amount of plasmid as was transfected
intohuman ovarian cancercellsusingDEAE dextran (16).
Although each ofthe lines was successfullytransfected,
only four (HuT 78, H9, MOLT-4, and WIL2-NS) success-
fully expressed chloramphenicol acetyltransferase ac-
tivity at 24 or 48 hr after transfection. The other four cell
lines studied have not been reported to have any DNA
repair deficits, and cell survival studies suggest that sen-
sitivity to cisplatin falls within the same broad range for
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FIGURE 2.Themeanadductvaluesareplottedforfourpatientswhowere
studied on each ofthe 6 designated study days. Each data point repre-
sents the mean value on that day, calculated from data for these four
individuals. (L) Data obtained fromcycle 1 oftherapy; (U) dataobtained
from cycle 2 oftherapy.
all eight cell lines (data not shown). These results indicate
that cellular factors that allow repair and expression of
transfected plasmid DNA mnot be present in all
peripheral blood leukoc es-even though there maybe no
apparentDNArepaideficiLwith respectto cellular DNA.
Host-Cell Reactivation ofCisplatin-
damaged Plasmid and Repair ofCellular
DNA in T-Cells
Results obtained using our host-cell reactivation assay
indicate that different subpopulations of blood cells have
different DNA repair capabilities. We therefore took the
approach that if we could study one cell type in each
individualwecouldassessrelative DNArepaircapabilities
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FIGURE 4. Two measures of DNA repair are related graphically for the
three human T-lymphocyte cell lines. The horizontal axis represents the
efficiency ofcells to repair transfected cisplatin-modified plasmid DNA.
The vertical axis represents the efficiency of cells to remove cisplatin
from cellular DNA, as measured by atomic absorption spectrometry.
betweenindividualsforthatcelltype. Ourfirstsubpopula-
tion ofinterest was T-lymphocytes: These cells are easily
obtained, can be easily developed into a pure culture, and
canbemaintainedwithoutviraltransformation for aperi-
od ofmonths.
We measured the ability of the three T-cell lines to
remove cisplatin from cellular DNA over 6 hr following
exposure to 10 ,uM ofthe drug for 1 hr. HuT 78, H9, and
MOLT-4 cells removed 5.6, 3.9, and 2.3 pgplatinum per ,ug
DNA, respectively. We next measured the ability ofthese
cells to repair transfected cisplatin-damaged pRSVcat,
using the host-cell reactivation assay. The Bo for each of
thecelllineswas22,18, and13,respectively. Plottingthese
twomeasures ofDNArepairagainstoneanothergivesthe
curve shown in Figure 4: the relationship is linear, with a
correlation coefficient of0.993.
HuT 78 H9 MOLT-4 WIL2-NS SKW6.4 RPMI 1788 THP-1 HL-60
Transfected Cell Lines
FIGURE 3. Efficiency oftransfection ofpRSVcat into each ofeight human leukocyte cell lines, described in the Methods. Solid columns represent the
percentuptakeof3H-labeledplasmidpriortoDNAsetreatmentofcells(totalcellularuptakeofplasmid). Hatchedcolumnsrepresentthepercentuptake
of3H-labeled plasmid after DNAse treatment ofcells (presumed to represent intracellular plasmid).
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Differences in Host-Cell Reactivation
between T- and B-Cells
It is currently unclear why only one ofthe three B-cell
lines successfully expressed chloramphenicol acetyl-
transferase activity after transfection with cisplatin-
modifiedplasmid. Itis ofnotethatthetwoB-celllinesthat
didnotexpress this activity(SKW6.4 and RPMI 1788) are
both Epstein-Barr virus-transformed cell lines, whereas
the WIL2-NS cell line is not. For the WIL2-NS cells, the
Bo is 8, which is lower than that ofany ofthe T cell lines;
and the IC50 for cisplatin is 1.02 p,M. Inclusion ofthe data
for WIL2-NS in the data set for T-cells results in a
breakdown of the mathematical relationship between the
two assays we used to assess DNA repair. Thus, the
relationship between DNA repair in cellular DNA and
repair oftransfected plasmid DNA holds only ifthe data
setisrestricted to onecelltype: T-cells. Further, transfor-
mation ofB cells by Epstein-Barr virus maybe disadvan-
tageous to the conduct ofthis assay.
Discussion
In the clinical studies presented here, a cohort of 21
patients with 15 types of tumor received cisplatin and
carboplatin as the only therapy for their malignancy. The
relationship between platinum-DNA adduct level in
peripheral blood cells and disease response was highly
statistically significant,with asummarytwo-sidedp-value
of0.00011. In studies ofhuman ovarian cancer cells, DNA
repair appears tobe the mostimportant single component
ofcellular resistance to cisplatin (16). In analyses ofsam-
ples collected from patients at all the designated time
points in this study, the absence of repair/removal of a
portion of drug-induced DNA damage from peripheral
blood cells appeared to contribute to an accumulation of
adductstohigherthanexpectedlevels. Understandingthe
molecular processes that occur in patients will require
direct study of cells from treated individuals. For that
reason,wehave developed ahost-cell reactivation assayto
assess cisplatin-DNA adduct repair capacity in human
T-cells.
Human T-lymphocytes have been selected for study for
several reasons. First, a close parallel between blood
tissue and tumor tissue in the processing of platinum-
DNAdamage is stronglysuggested bythedatapresented
here andprevious studies (5-8) and hasbeen confirmed in
studies ofautopsied patientswhoreceivedplatinum-based
therapy ante mortem (10). Second, different subpopula-
tions of blood cells may be biologically different, so it is
important to study the same cell type from all patients. T
Cells are easily obtained and cultured, and DNA repair
activity canbereadily assessedbyanassaythatis amena-
ble to the study ofmany samples-the host-cell reactiva-
tion assay.
In our studies, 30% ofthe adduct load seen in peripheral
blood cells 24 hr after a cisplatin dose maypersist for 2 25
days. The studies done by Fichtinger-Schepman and col-
leaguesindicate thatthe adductload at24hrmayrepresent
about one-quarter of the initial level of DNA damage (21).
The persistent platinum-DNA adduct load may therefore
represent 5-10% of the initial level of DNA damage
induced by a cisplatin dose. Subsequent administration of
carboplatin gives rise to the expected increase in DNA
adduct level, whereas subsequent administration of
cisplatin gives rise to a greater than expected increase in
DNAadductlevel(Fig.2).Onepossibleexplanationforthis
finding may be that cisplatin covalently attacks DNA
repair enzymes, in a fashion similar to its documented
attack on kidney enzymes (1,2), and may thus partially
inactivate DNA repair function.
Although many conclusions can be drawn from data
generated bymeasuring DNAdamage levels, afunctional
assessment ofDNA repair capability would be important
to test the validity of the hypotheses raised. Although
measurementoflevels ofexpressionofhuman DNArepair
genes and of the protein levels of relevant DNA repair
enzymes would be important, a functional assessment of
repair would overcome questions about artifactually ele-
vated mRNAlevels orhigh levels ofenzyme thatmightbe
partially dysfunctional. For these reasons, the host-cell
reactivation assay (which correlates well with cellular
repair ofcisplatin-DNA lesions in T-cells) shows promise
as a means ofaddressing these questions.
Although many factors may contribute to resistance to
cisplatin in vitro and in the clinic, an increasing body of
evidence suggests that DNA repair is the single most
important factor governing clinically relevant levels of
resistance.Theabilitytomeasureplatinum-DNAdamage
levels following therapeutic exposures has constituted the
first major step in unraveling the questions of clinical
resistance to platinum compounds. The nextmajor step is
to address the underlying molecular mechanisms which
may modulate the level of DNA damage.
This manuscript was presented at the Conference on Biomonitoring
and Susceptibility Markers in Human Cancer: Applications in Molecular
Epidemiology and Risk Assessment that was held in Kailua-Kona,
Hawaii, 26 October-1 November 1991.
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